Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 18Myelodysplastic Syndromes 4Leukemia, Myeloid 2Carcinoma, Non-Small-Cell Lung 2Targeted Therapy 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

fludarabine 8Specimen Handling 8Cyclophosphamide 7ruxolitinib 5Whole-Body Irradiation 5Stem Cell Transplantation 5Biopsy 5Azacitidine 5venetoclax 4Tacrolimus 4Injections 4Cytarabine 4Busulfan 4ivosidenib 3fludarabine phosphate 3Thiotepa 3Mycophenolic Acid 3Melphalan 3Cyclosporins 3CPX-351 3Blood Specimen Collection 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3luspatercept 2X-Rays 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Liposomes 2Gemtuzumab 2Daunorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Myeloproliferative Disorders × gilteritinib × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡